endocrinology
Type 2 diabetes

New type 2 players in their right treatment place

SGLT-2 inhibitors and GLP-1 analogues are in the right place as second line therapies in type 2 diabetes, a study presented at conference has concluded. The research presented by endocrinologist Dr David Hoffman from the Australian Diabetes Informatics Group (DINGO) set out to test the efficacy and durability of SGLT-2 inhibitors with GLP-1 analogues in ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic